ImClone deal

IMCL (New York) received an exclusive worldwide license from Cancer Research Campaign Technology Ltd. (U.K.) to a cancer vaccine that uses a monoclonal anti-idiotypic antibody. Cancer Research is the technology licensing arm of the Cancer Research Campaign. ...